<DOC>
	<DOCNO>NCT02387996</DOCNO>
	<brief_summary>The purpose study measure effect nivolumab ( BMS-936558 ) reduce tumor size subject metastatic unresectable bladder cancer .</brief_summary>
	<brief_title>A Study Nivolumab Participants With Metastatic Unresectable Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Evidence metastatic surgically unresectable transitional cell carcinoma urothelium involve bladder , urethra , ureter renal pelvis Measurable disease CT MRI Progression recurrence treatment ) With least 1 platinumcontaining chemotherapy regimen metastatic surgically unresectable locally advanced urothelial cancer , ii ) Within 12 month perioperative ( neoadjuvant adjuvant ) treatment platinum agent set cystectomy localized muscleinvasive urothelial cancer Subject receive 2 prior line chemotherapy must liver metastasis Tumor tissue ( archived new biopsy ) must provide biomarker analysis Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Subjects active cancer spread central nervous system Prior malignancy active within previous 3 year except locally curable cancer apparently cure Subject active , know suspected autoimmune disease Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration Prior treatment antiPD1 , antiPDL1 , antiPDL2 , anticytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) antibody , antiCD137 antibody drug specifically target Tcell costimulation immune checkpoint pathway Exclusion laboratory criterion : Positive test hepatitis B virus surface antigen ( HBV Ag ) hepatitis C virus ribonucleic acid ( HCV antibody ) indicate acute chronic infection Known history test positive human Immunodeficiency virus ( HIV ) know acquired Immunodeficiency syndrome ( AIDS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>